Phillips J, Ansel G
Cardiology, Internal Medicine Ohio Health Riverside Methodist Hospital, Columbus, OH 43214, USA.
J Cardiovasc Surg (Torino). 2013 Jun;54(3):333-6.
Endovascular treatment of symptomatic peripheral arterial disease in the femoropopliteal (FP) artery is fraught with high rates of restenosis. Success of the antiproliferative drug, paclitaxel, in the coronary arteries, has lead to the investigation of paclitaxel in the peripheral arteries to treat restenosis. This article reviews restenosis rates for the major treatment modalities used in the FP segment. Use of drug-elution for restenosis is also reviewed, including the use of drug-eluting balloons and drug-eluting stents.
股腘（FP）动脉症状性外周动脉疾病的血管内治疗面临着高再狭窄率的问题。抗增殖药物紫杉醇在冠状动脉治疗中的成功，促使人们研究其在治疗外周动脉再狭窄方面的应用。本文回顾了用于FP段的主要治疗方式的再狭窄率。还对外周动脉再狭窄的药物洗脱治疗应用进行了综述，包括药物洗脱球囊和药物洗脱支架的使用。
